CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Total revenues	$ 225,508	$ 143,096
Cost of revenues	122,918	83,862
Gross profit	102,590	59,234
Operating expenses:
Selling, general and administrative	44,298	50,160
Research and development	19,022	14,962
Patent litigation	1,319	960
Total operating expenses	64,639	66,082
Income (loss) from operations	37,951	(6,848)
Other income (expense):
Interest expense	(8,331)	(3,975)
Interest income	333	284
Reserve for Turing receivable	(48,043)	0
Other, net	596	(166)
Income (loss) before income taxes	(17,494)	(10,705)
Benefit from income taxes	(7,086)	(4,372)
Net loss	$ (10,408)	$ (6,333)
Net loss per common share:
Basic (in Dollars per share)	$ (0.15)	$ (0.09)
Diluted (in Dollars per share)	$ (0.15)	$ (0.09)
Weighted-average common shares outstanding:
Basic (in Shares)	70,665,394	68,967,875
Diluted (in Shares)	70,665,394	68,967,875
Impax Generics, net
Revenues:
Total revenues	$ 170,079	$ 128,741
Impax Specialty Pharma, net
Revenues:
Total revenues	55,429	$ 14,355
Turing Pharmaceuticals AG
Other income (expense):
Reserve for Turing receivable	(48,043)
Benefit from income taxes	$ (17,400)